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Approaches to classifying neuropsychological impairment after brain tumor vary accord-
ing to testing level (individual tests, domains, or global index) and source of reference
(i.e., norms, controls, and pre-morbid functioning). This study aimed to compare rates
of impairment according to different classification approaches. Participants were 44 indi-
viduals (57% female) with a primary brain tumor diagnosis (mean age=45.6 years) and
44 matched control participants (59% female, mean age= 44.5 years). All participants
completed a test battery that assesses pre-morbid IQ (Wechsler adult reading test), atten-
tion/processing speed (digit span, trail making test A), memory (Hopkins verbal learning
test-revised, Rey–Osterrieth complex figure-recall), and executive function (trail making
test B, Rey–Osterrieth complex figure copy, controlled oral word association test). Results
indicated that across the different sources of reference, 86–93% of participants were
classified as impaired at a test-specific level, 61–73% were classified as impaired at a
domain-specific level, and 32–50% were classified as impaired at a global level. Rates
of impairment did not significantly differ according to source of reference (p>0.05); how-
ever, at the individual participant level, classification based on estimated pre-morbid IQ was
often inconsistent with classification based on the norms or controls. Participants with brain
tumor performed significantly poorer than matched controls on tests of neuropsychologi-
cal functioning, including executive function (p=0.001) and memory (p<0.001), but not
attention/processing speed (p>0.05).These results highlight the need to examine individ-
uals’ performance across a multi-faceted neuropsychological test battery to avoid over- or
under-estimation of impairment.
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INTRODUCTION
Brain tumor is rare (6.4/100,000 worldwide), but has one of the
lowest survival rates of all cancers (1). Tumors of the central ner-
vous system are classified according to the cells or tissue in which
the tumor grows, as well as the grade or malignancy (2). Malig-
nant brain tumors (Grades III–IV) are cancerous, grow rapidly,
and are associated with poorer prognosis for survival. Low grade
gliomas (Grades I–II) are histologically benign, but may recur or
progress, particularly if complete removal is not feasible (2–4).
Other benign tumors (e.g., meningiomas) rarely recur but can
seriously affect neurological functioning (5). The site of tumor
growth is typically related to neuropsychological deficits (e.g., left
hemisphere tumors commonly affect language). However, due to
compression and displacement effects more widespread damage
and global neuropsychological impairment can occur (5).
The severity and nature of neuropsychological impairment is
a key factor influencing quality of life in people with brain tumor
(6). Obtaining accurate information about a person’s neuropsy-
chological status is central to planning their rehabilitation and
supportive care (5, 6). Moreover, neuropsychological functioning
has been found to be related to prognosis and tumor recurrence
and may be more sensitive in predicting early tumor recur-
rence than imaging techniques (7–9). Accordingly, research in the
brain tumor field has focused on the nature of neuropsychologi-
cal impairment, relationships between neuropsychological status,
tumor type, location, and size, and the impact of impairments on
everyday functioning (7–11).
There is a considerable variability in the rates of neuropsycho-
logical impairment reported in brain tumor studies. For example,
rates of neuropsychological impairment have been found to vary
from 12.5 to 91% (10–16). A key reason for such variability appears
to be the different methods for assessing and interpreting per-
formance on neuropsychological tests. Three broad approaches
to analysis or classifying impairment are evident across studies
(10–16): test-specific analysis classifies impairment on the basis
of an individual test (e.g., a particular memory test); domain-
specific analysis determines impairment based on a compos-
ite of test scores that relate to a particular neuropsychological
domain (e.g., attention/processing speed); and a global index of
neuropsychological impairment involves calculating a composite
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across different domains of cognitive ability (e.g., summing and
averaging standardized scores across tests of several cognitive
domains).
To date, few studies have compared rates of neuropsychological
impairment according to the level of impairment (i.e., test-specific,
domain-specific, and global indices). Tucha et al. (11) reported
that rates of neuropsychological impairment were 91, 60–78, and
17% for test-specific, domain-specific, and global indices, respec-
tively. Other researchers have compared impairment rates across
two different levels of classification. For example, Talacchi et al.
(10) found that 79% of a glioma sample was impaired on at least
one neuropsychological test (i.e., test-specific level), whereas rel-
atively fewer (i.e., 38%) were impaired at a domain-specific level.
Lageman et al. (12) examined impairment rates at a test-specific
level only, and reported that 59% of participants were impaired
based on their conservative criteria (i.e.,>2 SD below the norms).
Besides the issue of different levels for classifying impairment,
a further potential concern in the brain tumor literature relates to
the common approach of categorizing a person as impaired based
solely on cut-off scores derived from normative data (11). Accu-
rate interpretation of a person’s neuropsychological functioning
in the context of neurological disorder is reliant on an under-
standing of his or her level of pre-morbid intellectual functioning.
This helps to avoid an overestimation or underestimation of any
deficits evident on testing (17). For example, individuals who
were previously functioning in the superior intellectual range may
not demonstrate neuropsychological impairment relative to the
norms (17). However, they may still experience significant deficits
relative to their own pre-morbid functioning. Although it is com-
mon in clinical practice to measure estimated pre-morbid IQ to
assist interpretation of neuropsychological test results after brain
tumor, a comparison between rates of impairment based on nor-
mative data and impairment relative to pre-morbid functioning
(i.e., relative to self) has yet to be conducted.
There is also a paucity of studies utilizing a matched control
group to investigate the nature of neuropsychological impairments
experienced after a brain tumor. Although normative data are
available for the majority of neuropsychological tests, these data
are often dated and demographic characteristics are often not well
matched to participants with brain tumor (11). Studies employing
a matched control sample typically report that participants with
brain tumor display significantly poorer global neuropsychologi-
cal functioning than controls (14, 15). For example, Bosma et al.
(14) reported significant differences between the brain tumor and
control samples on the domains of psychomotor function, work-
ing memory, processing speed, and attention. A comparison of
rates of neuropsychological impairment according to source of
reference is needed to determine whether different approaches
yield comparable findings.
THE PRESENT STUDY
The main aim of the present study was to determine within the
same sample whether rates of neuropsychological impairment
vary according to source of reference (i.e., test norms, controls,
and estimated pre-morbid IQ). Rates of impairment were exam-
ined according to three different levels of analysis (test-specific,
domain-specific, and global functioning). Given that few brain
tumor studies have employed a control sample, a further aim was
to compare the neuropsychological functioning of participants
with brain tumor and a control sample matched on age, gender,
education, and estimated IQ. It was hypothesized that participants
with brain tumor would demonstrate significantly poorer atten-
tion/processing speed, memory, and executive functioning than
matched controls.
MATERIALS AND METHODS
PARTICIPANTS
Brain tumor sample
Forty-four participants were recruited from the community as
part of a broader study on psychosocial outcomes of brain
tumor. For the present study, only participants with primary brain
tumor (benign or malignant) were included and those with a
secondary tumor or metastases or recurrent multiple tumor diag-
noses were excluded. Participants were required to be at least
1 month post diagnosis prior to undertaking the assessment, aged
18–75 years, and demonstrate adequate receptive and expressive
English language skills.
Participants were recruited from a variety of sources includ-
ing a brain tumor support service, cancer counseling services,
neurosurgery clinics, and a brain injury outreach service. Partic-
ipants included 19 males (43%) and 25 females (57%) with an
age range of 21–71 years (M = 45.57, SD= 11.72) and time since
diagnosis between 1.5 months and 22 years (M = 4.26, SD= 5.05).
Education level for the brain tumor sample ranged from 7 to
19 years (M = 12.84, SD= 2.77) and estimated pre-morbid IQ
(Wechsler test of adult reading) varied between 88 and 119
(M = 103.27, SD= 7.97). Medical reports indicated the follow-
ing tumor types: glioblastoma multiforme (n= 9), oligoden-
droglioma (n= 9), astrocytoma (n= 7), meningioma (n= 6),
unspecified type of glioma (n= 6), colloid cyst (n= 3), cranio-
pharyngioma (n= 3), and ganglioglioma (n= 1). Sixteen partic-
ipants had tumors located in the right hemisphere, 15 in the left
hemisphere, and 13 participants had medial or bilateral tumors.
Table 1 presents the demographic and clinical characteristics of
the participants with brain tumor. The majority of the sam-
ple had received surgery as their primary treatment (84%), with
20% also receiving radiotherapy and/or chemotherapy. Partici-
pants with benign tumors in the third ventricle, insula, or brain
stem regions had typically not received surgery at the time of the
study.
Control sample
Control participants were recruited through either a university
research participant pool or the first author’s social network. Par-
ticipants were included in the study if they were aged 18–75 years,
spoke English fluently, and had no history of a neurological event
or other medical condition, which may impact on cognitive func-
tioning. Recruitment particularly focused on adults across the
age bands of 20–35, 36–55, and 56–71 years to ensure a simi-
lar age profile to the brain tumor sample. As shown in Table 1,
the matched control sample included 44 participants (41% male)
aged 26–71 years (M = 44.45, SD= 12.96), with an education level
of 9–20 years (M = 12.61, SD= 2.36), and estimated IQ range
of 90–116 (M = 105.16, SD= 6.67). The two samples did not
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Table 1 | Demographic, clinical variables, and comparison of brain
tumor and matched control participants.
Variables BT participants
(n=44)
Control
participants
(n=44)
Statistical
difference
N (%), M (SD),
range
N (%), M (SD),
range
Age (years) 45.57 (11.72) 44.45 (12.96), t =0.42,
21–71 26–71 p=0.67
20–35 11 (25.0%) 12 (27.3%)
36–55 24 (54.5%) 21 (47.7%)
56–75 9 (20.5%) 11 (25%)
Gender
Male 19 (43.2%) 18 (40.9%) χ2=0.047,
p=0.83
Female 25 (56.8%) 26 (59.1%)
Education (years) 12.84 (2.77), 12.61 (2.56), t =0.41,
7–19 9–20 p=0.68
7–10 years 11 (25.0%) 8 (18.2%)
11–12 years 14 (31.8%) 18 (40.9%)
>12 years 19 (43.2%) 18 (40.9%)
Estimated IQ 103.27 (7.97) 105.16 (6.67) t =−1.20,
p=0.23
Range 88–119 90–116
>110 7 (15.9%) 11 (25%)
90–110 34 (77.3%) 33 (75%)
<90 3 (6.8%) 0
Time since diagnosis 4.26 (5.05),
0.13–22
0–5 years 31 (70.5%)
6–10 years 7 (15.9%)
>10 years 6 (13.6%)
Histology
Malignant 19 (43.2%)
Benign or low grade 25 (56.8%)
Hemisphere
Left 15 (34.1%)
Right 16 (36.4%)
Bilateral/other 13 (29.5%)
Location
Frontal 24 (54.5%)
Temporal 3 (6.8%)
Parieto-occipital 2 (4.5%)
Brain stem/ventricle 5 (11.4%)
Other 10 (22.7%)
statistically differ on age, gender, education, or estimated IQ (see
Table 1).
MEASURES
Neuropsychological functioning was assessed on verbal and non-
verbal measures in the domains of attention/processing speed,
memory, and executive function. Eight scores on five tests were
converted to age-adjusted standardized scores (i.e., z-scores) based
on normative data. Scores were summed and averaged to derive
composite scores within each domain and a global index of
neuropsychological impairment [see Ref. (7) for use of the same
approach].
Attention/processing speed
Digit span. The digit span subtest of the Wechsler adult intelli-
gence scale-third edition [WAIS-III (18)] has been found to be a
reliable and valid measure of auditory attention and short-term
memory (19, 20). Digit span forward consists of 16 trials, com-
mencing with 2 digits and ending with 9 digits, with a maximum
possible score of 16. Digit span backward measures working mem-
ory or mental manipulation (19, 20). Digit span backward consists
of 14 trials starting with 2 digits and ending with 8 digits, with a
maximum score of 14. The digit span total raw score was converted
to an age-adjusted z-score based on the WAIS-III norms (18).
Trail making test A. The trail making test [TMT, Partington and
Leiter, 1949, as cited in Ref. (20)] is a reliable and valid measure of
visual and focused attention/processing speed (20). TMT part A
(TMT-A) requires participants to connect circles numbered from 1
to 25 in order as quickly as possible. The test is timed and scoring
is based on time taken (seconds) to complete the test, includ-
ing any error correction time. The raw score was converted to an
age-adjusted z-score based on normative data (20).
Memory
Hopkins verbal learning test-revised. The Hopkins verbal learn-
ing test-revised (HVLT-R) is a standardized measure of learning
rate and immediate and delayed verbal recall (21, 22). The HVLT-
R consists of a list of 12 words (four words from three semantic
categories), which is read out aloud three times with the partic-
ipant required to immediately recall as many words as possible
after each list. Approximately 20 min later, participants are asked
to recall the list read earlier. The HVLT-R total recall is scored
by adding together the total number of words recalled in the first
three trials; delayed recall is scored by the number of words remem-
bered in the fourth trial. The raw scores for total words recalled
and delayed recall were converted to age-adjusted z-scores based
on the norms (21).
Rey–Osterrieth complex figure (recall). The Rey–Osterrieth
complex figure (RCF) consists of a complex geometric design that
participants are initially asked to copy as accurately as possible
(20). The visual memory component of the RCF involves partici-
pants redrawing the figure from memory at an allocated time after
the copy trial. In this study, participants were asked to redraw the
figure approximately 30 min after copying the figure, thus assess-
ing delayed memory. The raw score out of 36, based on scoring
guidelines by Osterrieth [1944, as cited by Strauss et al. (20)], was
converted to an age-adjusted z-score.
Executive functions
Rey–Osterrieth complex figure (copy). The copy trial of the RCF
is considered a valid measure of planning and organization, based
on the accuracy in which the geometric figure is copied. The same
scoring system used for RCF recall was used for RCF copy (20).
Trail making test B. Trail making test part B (TMT-B) is
considered to be a measure of mental flexibility, which requires
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participants to alternate between connecting numbers and letters
in numerical and alphabetical order. Similar to TMT-A, the
TMT-B score is based on time taken to complete the test, including
any error correction time (20). However, the use of TMT-B minus
TMT-A (B–A in seconds) has been recommended as a more sensi-
tive measure of executive control, and thus an age-adjusted z-score
was calculated for this index in the present study using normative
data (20).
Controlled oral word association test. The controlled oral word
association test (COWAT) is a standardized measure of verbal flu-
ency, word retrieval, and self-regulation (20). Participants are told
a letter of the alphabet and instructed to generate as many words
as possible beginning with that letter according to the rules (i.e.,
to avoid proper nouns, word derivatives, and repetitions). Partic-
ipants have 1 min for each of the three letters administered (F,
A, and S). The total number of correct words across the three
trials was converted to an age-adjusted z-score using normative
data (20).
Estimated pre-morbid IQ
Estimated pre-morbid IQ was measured using the Wechsler test
of adult reading [WTAR; (23)]. The WTAR is a reliable and valid
measure of pre-morbid IQ following brain injury (24). This word
pronunciation test consists of 50 English language words that
become progressively more difficult to pronounce. As per the
manual instructions, one point was scored for each correctly pro-
nounced word, and the total raw score was converted to a predicted
IQ score based on age-adjusted norms (23).
PROCEDURE
Following ethical clearance from a university human ethics review
committee and informed consent procedures, participants with
brain tumor and control participants were individually adminis-
tered the battery of neuropsychological tests in the following stan-
dardized order: WTAR, RCF (copy), HVLT-R (learning trials and
immediate recall), COWAT, TMT-A, TMT-B, digit span, HVLT-R
(delayed recall), and RCF (recall). Testing was conducted in the
participants’ own homes in a quiet place with no distractions.
STATISTICAL ANALYSIS
Data screening was conducted using SPSS 21 to examine accu-
racy of data entry, missing values, outliers, and normality. For
each source of reference, the proportion of participants with brain
tumor classified as impaired at the test-specific, domain-specific
(attention/processing speed, memory, and executive function),
and global level were calculated as follows.
Test norms
As commonly recommended in the literature (20, 25), an age-
adjusted z-score of ≤−1 was used to indicate impairment (note:
this was used to denote at least mild impairment). Participants
with an age-adjusted z-score of ≤−1 on at least one of the eight
neuropsychological tests were classified as “impaired” at the test-
specific level, while those with scores of>−1 on all tests were clas-
sified as “not impaired.” Participants with an age-adjusted z-score
composite of≤−1 on at least one of the three domains (attention/
processing speed, memory, and executive function) were classified
as “impaired” at the domain-specific level and those with scores
of >−1 on each domain were classified as “not impaired.”
Participants with an average age-adjusted z-score of ≤−1 on
the eight neuropsychological test scores [i.e., global impairment
index= (8× z-scores)/8], were classified as “impaired” at the
global level, and those with a global impairment index of >−1
were classified as “not impaired.”
Matched controls
To classify impairment relative to matched controls, the following
three age bands were established: 21–35 years (n= 12), 36–55 years
(n= 21), and 56–71 years (n= 11). Participants with brain tumor
were classified as impaired or not impaired using the data for their
age band (i.e., impaired= score≤1 SD below the mean). The raw
score and age-adjusted z-score means on each test for the brain
tumor and matched control samples are presented in Table 2.
Estimated pre-morbid IQ (relative to self)
A number of steps were used to classify impairment relative to
self. Participants’ estimated pre-morbid IQ on the WTAR was
initially converted to a standardized score adjusted for age (i.e.,
z-score). One z-score was then subtracted from this standard-
ized score to provide an individualized cut-off point at which a
participant would be considered impaired (20). For example, one
participant with brain tumor had a standardized IQ score of 0.82
relative to the WTAR norms. Subtracting one z-score from 0.82
yielded a cut-off score of −0.18. This participant was classified as
impaired if scores on the neuropsychological test, composite, and
global indices were ≤−0.18.
Two-proportion Z -tests were conducted to compare rates of
participants classified as impaired according to source of refer-
ence. Due to the dichotomous nature of the data, the weighted
crosstabs procedure was used in SPSS to produce a Pearson Chi
Squared statistic. A square root of this statistic was calculated to
yield the two-proportion z-statistic [see Ref. (26)].
Between-group analyses were conducted to compare the neu-
ropsychological functioning of participants with brain tumor and
matched controls. A MANCOVA was conducted to examine group
differences on the combination of the three neuropsychologi-
cal domains (i.e., neuropsychological composite), controlling for
relevant covariates. Univariate analyses with a Bonferroni correc-
tion were used to examine group differences for the domains of
attention/processing speed, memory, and executive function.
RESULTS
COMPARISON OF IMPAIRMENT RATES ACCORDING TO SOURCE OF
REFERENCE
A comparison of impairment rates according to source of refer-
ence identified the same pattern of results across the test-specific,
domain-specific, and global levels. Specifically, as presented in
Table 3, for each source of reference a higher proportion of par-
ticipants were classified as impaired at a test-specific level than
at a domain-specific level, and at a domain-specific level than at
a global composite level. Further, the results of two-proportion
z-tests indicated no significant differences in rates of impairment
according to source of reference (p> 0.05). Overall, participants
were most likely to be classified as impaired at the test-specific
level when relative to self was used as the source of reference. This
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Table 2 | Raw score and age-adjusted normative Z -score means for the brain tumor and control groups.
Domain Test Brain tumor group Control group
Raw scores Age-adjusted z-scores Raw scores Age-adjusted z-scores
M SD M SD M SD M SD
Attention/processing speed DS 16.64 4.32 0.06 0.96 17.45 3.99 0.21 0.96
TMT-A 36.03 12.98 −0.42 1.30 28.11 8.74 0.35 0.78
Memory HVLT-T 23.00 5.36 −1.35 1.41 26.39 3.98 −0.54 1.03
HVLT-D 7.30 3.32 −1.65 1.94 9.73 1.85 −0.27 1.08
RCF-R 16.85 7.08 0.06 1.10 22.75 4.70 0.88 0.71
Executive functions RCF-C 31.74 3.64 −0.08 1.21 34.70 1.25 0.93 0.41
COWAT 32.25 12.78 −0.73 1.22 46.93 10.89 0.64 0.98
TMT-B-A 51.46 53.80 −1.38 4.07 37.95 17.98 −0.39 1.21
COWAT, controlled oral word association test; DS, digit span; HVLT, Hopkins verbal learning test (T=Total, D=Delayed); RCF, Rey complex figure (C=Copy, R=Recall);
TMT, trail making test (TMT-A=Trails A, TMT-B-A=Trails B minus Trails A).
Table 3 |Two-proportion Z -tests on rates of brain tumor participants classified as impaired according to source of reference.
Source of reference % Impaired on at least one test % Impaired on at least one domain % Impaired on global composite
Norms 86.40a 61.40d 31.80g
Matched controls 90.90b 72.70e 50.00h
Self (estimated pr-emorbid IQ) 93.20c 70.50f 40.90i
Two-proportion z -statistic abz =0.67, p=0.50 ns dez =1.06, p=0.26 ns ghz =1.73, p=0.08 ns
acz =1.06, p=0.29 ns dfz =0.90, p=0.37 ns giz =0.89, p=0.38 ns
bcz =0.39, p=0.69 ns efz =0.24, p=0.81 ns hiz =0.86, p=0.39 ns
finding indicates that most participants (i.e., 93%) performed ≥1
z-score below their estimated pre-morbid on at least one test.
However, similar findings were evident at the test-specific level for
the norms (86%) and matched controls (91%). Although group-
level rates of impairment did not differ substantially according to
the source of reference, it was also relevant to determine whether
the same individuals were classified as impaired or not impaired
for these three sources of reference.
As a supplementary analysis, an inspection of individual par-
ticipant data identified that 89% were classified the same (i.e.,
impaired or not impaired) at the test-specific level, 73% were clas-
sified the same at the domain-specific level, and 64% were classified
the same at the global level. Notably, inconsistencies were most
common between the classification based on relative to self and
those based on the norms and matched controls.
NEUROPSYCHOLOGICAL FUNCTIONING OF PARTICIPANTS WITH BRAIN
TUMOR AND CONTROLS
As shown in Table 4, a one-way between-groups MANCOVA
revealed a significant effect of the covariate of estimated IQ on the
neuropsychological composite (p< 0.05), whereas education was
not significant (p= 0.14 ns). A significant difference was found
between the brain tumor and control groups on the neuropsycho-
logical composite, Pillai’s trace= 0.20, F (3, 82)= 6.72, p< 0.001,
η2= 0.20. Consequently, univariate main effects were examined
using analysis of covariance (ANCOVA). Due to violation of the
assumption of homogeneity for the memory domain and the
multiple comparisons, alpha level was adjusted to p< 0.016 for
the attention/processing speed and executive function domains,
and p< 0.008 for the memory domain to interpret the main
effects (27). The results of the ANCOVAs revealed significant
group differences for executive function (p= 0.001) and memory
(p< 0.001), as presented in Table 4. No significant group dif-
ference was found for attention/processing speed (p= 0.018 ns).
Matched controls performed significantly better on the domains
of memory and executive function than the participants with brain
tumor.
DISCUSSION
People with brain tumor commonly receive neuropsychological
assessments to monitor their cognitive and behavioral function-
ing and to assist in determining the impact of the tumor and its
treatment on everyday functioning (5). The accuracy of this assess-
ment is crucial given that opinions formed on the basis of these
assessments influence people’s perceptions of their illness and can
influence the type of support and rehabilitation provided. This
study primarily aimed to determine whether rates of neuropsy-
chological impairment after brain tumor vary according to the
source of reference. Overall, rates of neuropsychological impair-
ment did not significantly differ between classifications based
on normative data, matched controls, or estimated pre-morbid
IQ. Participants with brain tumor demonstrated poorer overall
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Table 4 | A comparison of neuropsychological functioning between the control and brain tumor groups.
Variables Control group (n=44) Brain tumor group (n=44) F p value η2
Neuropsychological functioning (z -scores)
MANCOVA results Pillai’s trace=0.20 6.72 <0.001 0.20
Estimated IQ Pillai’s trace=0.14 4.55 0.005 0.14
Education Pillai’s trace=0.05 1.35 0.26 0.05
ANCOVA results M SD M SD
Attention/processing speed 0.28 0.67 −0.18 0.95 5.79 0.018 0.07
Memory −0.13 0.71 −1.02 0.1.20 17.47 <0.001 0.17
Executive function 0.39 0.60 −0.73 1.78 13.02 0.001 0.13
neuropsychological functioning than matched controls, which was
mainly due to impairments in memory and executive function
rather than attention/processing speed.
COMPARISON OF IMPAIRMENT RATE ACCORDING TO SOURCE OF
REFERENCE
The main novel finding of this study is that, reassuringly, rates of
impairment did not substantially differ according to the source of
reference at any of the testing levels (i.e., test-specific, domain-
specific, or global). Further, most individuals were classified
consistently (i.e., impaired or not impaired) using approaches
based on the norms, matched controls, and estimated pre-morbid
IQ. Although the difference was not significant, classification of
impairment based on the control group was slightly higher than
impairment based on the norms. This may have occurred because
the control group performed relatively well on several of the
neuropsychological tests (i.e., RCF-C, RCF-R, and COWAT).
Examination of individual participant data indicated inconsis-
tent classification results for approximately one third of the sam-
ple. In particular, 27 and 36% of individuals were classified incon-
sistently across the sources of reference at the domain-specific and
global levels, respectively. In most cases, the inconsistency occurred
because classification of impairment based on pre-morbid IQ (i.e.,
relative to self) differed from classification of impairment based on
the norms or matched controls. Such results indicated two poten-
tial classification errors; namely, participants with an estimated
pre-morbid IQ in the low average range (i.e., WTAR predicted
IQ< 90) being incorrectly classified as “impaired,” and partici-
pants with an estimated pre-morbid IQ in the high average range
(i.e.,WTAR predicted IQ≥ 110) being incorrectly classified as“not
impaired.” Therefore, for a small but not insignificant subgroup of
participants, classification of impairment based on the norms or
matched controls may have yielded misleading results. This sup-
ports the need to interpret individuals’ neuropsychological test
results in the context of their estimated pre-morbid IQ.
Consistent with previous research by Tucha et al. (11), rates of
impairment were highest at the test-specific level (i.e., 86–93%)
for each source of reference. This result is likely to reflect normal
individual variability in cognitive performance, which is evident
for people without a neurological disorder (28). Thus, most peo-
ple with brain tumor in this study were classified as impaired on
at least one test. They were less frequently classified as impaired at
the domain-specific (61–73%) or global (32–50%) levels because
these reflect performance averages. Such findings suggest that the
use of a single test to infer the presence or absence of impairment
is likely to be misleading. This is especially the case for the brain
tumor population given that tumor location, size, and treatment
effects could lead to diverse presentations of neuropsychological
deficits (5, 10, 12). Furthermore, global indices of impairment that
are based on a composite of different tests may fail to reveal selec-
tive neuropsychological deficits as well as preserved abilities and
strengths. Previous research (11, 12) indicates that results from
both a range of individual tests and a global neuropsychologi-
cal index may be useful in distinguishing between focal and mass
effects caused by brain tumor. In particular, selective impairment
on testing is more likely to indicate focal effects and more gener-
alized impairment across a range of tests (i.e., global impairment)
may indicate mass effects (11).
Overall, the present findings support the need to examine indi-
viduals’ neuropsychological functioning across a multi-faceted
test battery and to also interpret findings in the context of their
estimated pre-morbid IQ to avoid either overestimation or under-
estimation of impairment. Interpretation based on a combination
of individual tests, domains, and a global index is optimal to pro-
vide a comprehensive profile of functioning for the treatment team
and individuals and their families. Such an approach can also assist
to identify preserved abilities or strengths that may assist individ-
uals to compensate for their neuropsychological deficits, guide
rehabilitation planning, and support the development of realistic
goals for home and community functioning (15).
Bearing in mind the advantages of conducting a comprehensive
neuropsychological assessment, a pragmatic issue surrounding
testing in both research and clinical contexts is that of specificity
versus brevity (12, 29, 30). Fatigue and psychological distress are
common for people with brain tumor and therefore a lengthy test
battery not only places burden on the individual but can also com-
promise the validity of test results. Therefore, a balance between
specificity and brevity is important for neuropsychological testing
to yield valid and meaningful information (12). Screening batteries
that assess multiple neuropsychological domains but also provide
a global index of functioning based on the same norms, such as the
repeatable battery for the assessment of neuropsychological status
(RBANS) (31), may have utility when a brief assessment (i.e., 25–
30 min) is warranted. Research by Lageman et al. (12) supported
the utility of the RBANS for assessing impairments in attention,
language, visuospatial construction, and immediate and delayed
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memory after brain tumor. However, the RBANS does not measure
executive functioning, which is essential given that research has
demonstrated that this domain is the most commonly impaired
after brain tumor (10, 11).
The response assessment in neuro-oncology [RANO; (29)]
working group and the international cognition and cancer task
force [ICCTF; (30)] proposed a core set of cognitive tests, which
include three of the tests administered in the present study. This
25–30 min core battery is commonly used to detect neurotoxicity
of brain tumor treatment and includes the HVLT (learning and
memory), trail making test (processing speed and executive func-
tion), and COWAT (verbal fluency) (29). All three tests have good
psychometric properties and demonstrated sensitivity to cognitive
dysfunction experienced by the neuro-oncology population (29).
The test battery employed in the present study took approximately
40–45 min to administer, and included an estimate of pre-morbid
IQ and verbal and non-verbal measures of attention/processing
speed, memory, and executive function. Although more stringent
criteria are typically used to define cognitive impairment in neu-
rotoxicity trials (30), the cut-off of ≤−1 z-score was used in the
present study to reflect at least mild impairment (i.e., <16thh)
(20). The selection of both the test battery and criteria for impair-
ment needs to be guided by the particular question/s posed in
research (e.g., is there evidence of neurotoxicity?) or clinical prac-
tice (e.g., would this person benefit from a referral for cognitive
rehabilitation?). Although the current battery was considered to
have good utility for screening purposes, a more comprehensive
test battery is likely to be required in various referral contexts, for
example, to determine vocational capacity.
NEUROPSYCHOLOGICAL FUNCTIONING OF PARTICIPANTS WITH BRAIN
TUMOR AND CONTROLS
Consistent with previous research (14, 15), participants with brain
tumor performed significantly poorer overall on tests of neuropsy-
chological functioning than matched controls. Their performance
was significantly impaired on the executive function and mem-
ory domains, but not on the attention/processing speed domain.
Talacchi et al. (10), and Tucha et al. (11), also reported higher
levels of impairment on tests of executive function and mem-
ory as compared to other domains; however, a control group
was not employed in these studies. However, unlike the find-
ings of Bosma et al. (14), participants in the present study did
not perform significantly poorer than controls on tests of atten-
tion/processing speed. Aside from different tumor characteristics,
a likely reason for the inconsistent findings between studies relates
to the selection of tests to assess neuropsychological function-
ing. This reflects a broader issue in the neuropsychological lit-
erature whereby researchers commonly employ different tests to
assess the same abilities, thus making comparisons between studies
difficult (29, 30).
In the present study, the attention/processing speed domain
was comprised of scores on digit span forward (auditory span-
ning), digit span backward (auditory spanning, working memory),
and TMT-A (visuo-motor scanning, focused attention, process-
ing speed) (19). A supplementary examination of between-group
differences on these tests revealed no significant differences on
digit span forwards or digit span backwards; however, participants
with brain tumor performed significantly poorer than controls
on TMT-A. A possible explanation for this finding is that func-
tions that rely on more localized neural networks (e.g., auditory
spanning and working memory) are less likely to show deficits
than functions that rely on more widely distributed networks
(visuo-motor scanning) (19, 32). This finding supports previ-
ous research indicating that attention/processing speed is not a
unitary construct and that dissociable components have a differ-
ent neuroanatomical basis (19). However, this explanation is only
speculative as precise neuro-imaging data were not available to
enable an investigation of the relationship between tumor location
and test performance in the present study.
LIMITATIONS
A further key limitation of this study relates to the convenience
sampling approach employed whereby participants had diverse
tumor characteristics and were assessed at varying time periods
after their diagnosis and treatment. In clinical practice, individu-
als with brain tumor may receive a neuropsychological assessment
prior to their primary treatment, soon after this treatment, or
at a more long-term phase of their illness (e.g., following tumor
recurrence). Therefore, the varied characteristics of the present
sample mirror many clinical settings. Nonetheless, further research
examining the extent to which classification approaches influence
the rate of neuropsychological impairment in a larger and more
homogenous brain tumor sample at the same stage of illness is
needed.
In particular, it would be beneficial to examine the relative risk
(with confidence intervals) of being classified as impaired or not
impaired according to different approaches to classification. Fur-
thermore, the present study focused on the presence or absence of
neuropsychological impairment, rather that the severity or degree
of impairment. Focus on the latter is also important given that
severity of neuropsychological impairment has been found to be
associated with quality of life after brain tumor in some stud-
ies (6). As a further study limitation, the −1 SD cut-off adopted
as the criterion for impairment increased the chances of people
with high IQ being misclassified as “impaired” because they were
more likely to have scores fall 1 SD below their estimated IQ. In
future research, the number of individual tests on which a per-
son is impaired may provide a more meaningful index of global
impairment rather than using a composite based on the average
z-score of the tests. This could be compared with estimates of
the expected number of impaired scores in the healthy popula-
tion using Monte Carlo simulations with comparisons based on
differing cut-off scores (e.g.,−1,−1.5,−2 SD).
CONCLUSION
Overall, a key novel finding of the present study was that rates
of neuropsychological impairment after brain tumor were gen-
erally comparable when classifications were based on the norms,
controls, and estimated pre-morbid IQ. Although using differ-
ent sources of reference may not produce major variations in
group-level rates of impairment, interpretation of test results
based on the test norms and a person’s estimated pre-morbid
functioning is likely to be most accurate. The selection of tests
in an assessment battery and criteria for impairment needs to be
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guided by the specific questions posed in the research and clinical
context. Nevertheless, ongoing efforts to improve consistency in
the approaches to administering and interpreting neuropsycho-
logical tests are expected to contribute to optimal management
and support for people with brain tumor.
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